Optivia Biotechnology Inc. is positioned to help drug developers address clinically significant transporter-related drug-drug interactions. In addition to its polarized mammalian cell assay, it is developing a platform for studying transporter biology and optimizing drug discovery and development.

Hungarian start-up Solvo Biotechnology is attempting to create therapeutics to treat multidrug resistance--a phenomenon describing a cancer cell's ability to resist the toxicity of chemotherapies. Solvo is developing compounds targeting molecular pumps that expel cytotoxic drugs from cancerous cells.